Board News and Announcements







NORTH CAROLINA MEDICAID AND NORTH CAROLINA HEALTH CHOICE STATEMENT CONCERNING PRIOR APPROVAL REQUIREMENTS FOR OPIOID PRESCRIPTIONS.  North Carolina is facing an opioid epidemic. Three North Carolinians die from an opioid-related overdose every day. Modifying clinical coverage policies to promote safe opioid prescribing is an essential and significant step to realize the vision of the North Carolina Opioid Action Plan to reduce opioid deaths by 20 percent by 2021. On August 27, 2017, prior approval became effective for Medicaid and NC Health Choice opioid prescribed analgesic doses that exceed 120 mg of morphine equivalents per day; are greater than a 14-day supply of any opioid; or are non-preferred opioid products on the North Carolina Medicaid Preferred Drug List. The Department of Health and Human Services (DHHS) worked closely with prescribing physicians and pharmacists to develop the best approach to reduce the oversupply of prescription opioids available for diversion and misuse, promote safe opioid prescribing for patients, and encourage alternative pain management, while minimizing administrative requirements as much as possible.

Opioid Prescriptions: Emergency Supply and Partial Fill

As a reminder, pharmacy providers may use the 72-hour emergency supply allowed for drugs requiring prior approval. Federal law requires that this emergency supply be available to Medicaid beneficiaries for drugs requiring prior approval (Social Security Act, Section 1927, 42 U.S.C. 1396r-8(d)(5)(B)). Use of this emergency supply will allow access to medically necessary medications until prior approval is obtained or a revised opioid prescription not requiring prior approval is received.

As an additional reminder, the Comprehensive Addiction and Recovery Act of 2016 (CARA), and the rules and regulations of the NC Board of Pharmacy, allow a North Carolina licensed pharmacy to provide a partial fill of a Schedule II controlled substance prescription when the prescription is written and filled in compliance with federal and state law, the partial fill is requested by the patient or the prescriber and the total quantity dispensed in all partial fills does not exceed the total quantity prescribed. The total amount of a Schedule II controlled substance prescription may be filled no later than 30 days from the date of the prescription.

If a pharmacist receives a verbal Schedule II controlled substance prescription pursuant to an emergency, the pharmacist may provide a partial fill, but must provide the remainder of the prescription amount within 72 hours. After 72 hours, no further dispensing on the emergency prescription is allowed. All other requirements regarding the need to receive a hard copy (or valid electronic) prescription within seven days remain.  More information is found here:

DHHS appreciates the partnership of prescribing physicians and pharmacists to combat the opioid crisis in North Carolina and to keep our fellow North Carolinians safe. Opioid safety and alternative pain management provider resources are available on the Medicaid Outpatient Pharmacy website and the Community Care of North Carolina Medicaid Opioid Safety Resources website.




**IMPORTANT** UPDATE FOR PHARMACISTS ON 2018 LICENSE RENEWAL PROCESS.  As pharmacists are aware, the Board of Pharmacy is changing over to a new information technology system, which will be used for 2018 license renewals.  To complete online license renewal for 2018, pharmacists will not have to enter their CE course titles or numbers.  Rather, pharmacists will attest that they have completed the requisite CE requirements for renewal.  It is, of course, imperative that pharmacists truthfully attest to having completed the requisite CE requirements for renewal.  For more information about CE requirement changes that go into effect January 1, 2018, pharmacists are directed to this FAQ:




NC Board of Pharmacy Announces New Online Licensing System - Register Now Through the Gateway

In an ongoing effort to increase efficiency and to provide the most secure platform possible for our licensees, registrants, and permittees, the NC Board of Pharmacy has transitioned to a new online licensing system. From this point forward, all renewals, new applications, forms, and updates will be submitted and managed through a single online Gateway:

This means that all licensees and registrants must create a profile.

The first step is to visit the Gateway at  and select REGISTER NOW. You will follow the prompts to enter contact and other information through our secure server to create a unique user name and password.

Once registered, your user name and password will grant you access to:

and many others, including pending applications. The Gateway will be the single portal through which all aspects of licensure and registration are managed by NC Board of Pharmacy staff.

Please contact us if you have questions once you complete the initial registration process.




So-Called “Canadian” Pharmacies are a Danger to Consumers, NABP Reports

MOUNT PROSPECT, IL – The National Association of Boards of Pharmacy® (NABP®) released the Internet Drug Outlet Identification Program Progress Report for State and Federal Regulators: August 2017. The report discusses how rogue online pharmacies exploit the American perception that Canadian pharmacies provide safe medication at a lower cost. Read more here.




The North Carolina Board of Pharmacy will be upgrading its on-line licensing system in the coming weeks.  When this transition is complete, Board staff anticipate that the licensing, permitting, and registration processes will be simpler and quicker for both applicants and Board staff.

Accomplishing this transition will require that Board staff take down current licensing, permitting, and registration processes for a short time.  Here is the transition plan:

Effective August 18, 2017, all applications – pharmacist license, CPP credentialing, technician registration, pharmacy permitting, DME facility permitting, dispensing physician/PA/NP registration – submitted using current forms and processes (on-line or mail) will not be accepted.  Likewise, required updates – e.g., name changes, pharmacist manager changes, pharmacy closure notifications, employment changes, and the like – using current forms and processes will not be accepted.  A “mail stop” will go into effect 4:30pm 8/18/2017.  Any mail-based application or update received after that date will be returned to sender.  Any application or update received prior to August 18, 2017 will be processed by Board staff.

Beginning August 30, 2017, the new on-line system will open to accept all license, permit, and registration applications.

Board staff will resume issuing licenses, registrations, and permits based on applications received in the new on-line system by September 6, 2017. 

Also beginning August 30, 2017, existing licensees, permittees, and registrants will need to connect to the new on-line system and create a profile there for purposes of renewal and/or required updates.  More information about the profile creation process will be communicated to all existing licensees, permittees, and registrants in the coming weeks.




The North Carolina Board of Pharmacy has an opening for an Information Technology Administrator. Please follow this link for a description of the position, qualifications needed, and details on how to apply.



The NC Department of Health and Human Services Division of Medical Assistance has outlined upcoming opioid criteria changes for pharmacists and other health professionals. Please follow this link to learn more about these changes, effective August 27, 2017.



TUESDAY, JULY 11, 2017

BOARD OF PHARMACY ISSUES GUIDANCE TO PHARMACISTS ON IMPLEMENTATION OF THE STRENGTHEN OPIOID MISUSE PREVENTION (“STOP”) ACT.  The North Carolina General Assembly has passed, and the Governor has signed into law, the Strengthen Opioid Misuse Prevention (“STOP”) Act.  The STOP Act is an effort to combat the opioid abuse and misuse epidemic.  The STOP Act makes changes to the laws governing controlled substance prescribing, controlled substance dispensing, and the North Carolina Controlled Substance Reporting System (“CSRS”).  This FAQ guidance discusses those changes:



TUESDAY, JULY 11, 2017

DEA ISSUES GUIDANCE STATEMENT ON TRANSFER OF “ON FILE” CONTROLLED SUBSTANCE PRESCRIPTIONS.  On April 12, Board staff posted an item concerning apparent confusion over the ability to transfer “on file” controlled substance prescriptions that have not been filled.  That notice stated that “if personnel at the DEA issue formal policy guidance” regarding such transfers, Board staff would advise pharmacists accordingly.  This email from Loren Miller, Associate Section Chief, Liaison and Policy Section, Diversion Control Division, Drug Enforcement Administration to Carmen Catizone, Executive Director, National Association of Boards of Pharmacy spells out DEA’s policy on this issue:


NEW CE OPPORTUNITIES: PHARMACISTS & TECHNICIANS, Remember to check our CE page often for upcoming CE programs in your area. (LAST UPDATED SEPTEMBER 8, 2017.)


FRIDAY, JULY 7, 2017

Patients Receiving Eculizumab (Soliris®) at High Risk for Invasive Meningococcal Disease Despite Vaccination. The CDC has issued a health advisory regarding the risk for invasive meningococcal disease in patients receiving eculizumab (Soliris). Investigations of invasive meningococcal disease should include inquiring about a history of receipt of eculizumab. Healthcare providers should maintain a high index of suspicion for meningococcal disease in patients taking eculizumab who present with any symptoms consistent with either meningitis or meningococcemia, even if the patient’s symptoms initially appear mild, and irrespective of the patient’s meningococcal vaccine or antimicrobial prophylaxis status.




The NCBOP was contacted by a North Carolina pharmacist in Wake County regarding a large prescription forgery ring.  Information indicated the ring involved individuals from the western part of NC, who are forging prescriptions for Phenergan w/Codeine.  The prescriptions bear the information of Alexis Benjamin, PA-C, DEA# MB2207252. 





Pharmacists and Technicians Need to Act **NOW** to Obtain an NABP e-Profile Number, or to Recover One Previously Obtained

New Board Rule .1516 (21 NCAC 46.1615) requires all pharmacists, technicians, pharmacies, and DME facilities to obtain and report to the Board a National Association of Boards of Pharmacy e-Profile Number.  Combined with the changes to the CE rules going into effect on January 1, 2018 (more info here:, this rule will further simplify the CE tracking process for pharmacists.  This requirement will also make it easier for Board staff to access and track information on continuing education fulfillment, pharmacy and DME facility inspections, and out-of-state disciplinary actions.  Note that there is no cost to obtain an e-Profile number. 

All pharmacists are required to report an NABP e-Profile Number in order to renew their licenses for 2018.  The vast majority of pharmacists already have an e-Profile number, as one is required to obtain credit for ACPE-accredited continuing education coursework.  Any pharmacist who does not have an e-Profile number or who does not remember his/her e-Profile number can obtain one (or recover one) through NABP at no cost.  Detailed instructions are found here:

All pharmacy technicians are required to report an NABP e-Profile Number in order to renew their registrations for 2018.  All PTCB-certified technicians already have an e-Profile number, which was assigned at the time of certification. Registered technicians may obtain one through NABP.  Any technician who does not have an NABP e-Profile Number or who does not remember his/her NABP e-Profile Number can obtain one (or recover one) through NABP at no cost.   Detailed instructions are found here:

Pharmacies and DME Facilities
Pharmacies and DME facilities will not be required to obtain and report an NABP e-Profile Number to renew permits for 2018.  Board staff is working with NABP staff to determine the most efficient method for pharmacies and DME facilities to obtain an e-Profile number.  At such time as that process is developed, information will follow from Board staff.  For now, pharmacies and DME facilities do not need to contact NABP about obtaining an e-Profile number.  Again, when a process is in place for assignment of e-Profile numbers to pharmacies and DME facilities, Board of Pharmacy staff will communicate that to pharmacies and DME facilities.


Pharmacists Should Act **NOW** To Register for Access to the North Carolina Controlled Substance Reporting System

The North Carolina General Assembly has passed, and the Governor has signed into law, the Strengthen Opioid Misuse Prevention (“STOP”) Act.

Among other things, the STOP Act requires all pharmacists to register for access to the North Carolina Controlled Substance Reporting System (“CSRS”), with a narrow exemption.

As a condition of renewing a pharmacist license for 2018, a pharmacist must attest either:  (a) he/she has registered for CSRS access; or (b) he/she is not employed in a pharmacy practice setting where Schedule II, III, or IV controlled substances are dispensed from a North Carolina-based facility or to North Carolina patients.
Any pharmacist who does not already have a CSRS access registration should immediately apply for one.  Pharmacists can access a simple, on-line application here: 

MONDAY, JUNE 26, 2017

Notice of Request for Early Review by Rules Review Commission and Right to Object

The Board of Pharmacy is engaged in the process of periodic review of its rules under N.C. Gen. Stat. Section 150B-21.3A.  The Board has proposed whether each one of its rules should remain in the Administrative Code, be removed or be readopted; has received public comments on those categorizations; has considered those public comments; and has adopted a final report categorizing its rules.

The next step in the process is for the North Carolina Rules Review Commission (the “RRC”) to review that report and issue a final determination on the categorization of the rules.  That review is currently scheduled for June 2018.  However, because the Board has already prepared its final report and would like to accelerate the process of streamlining its regulations, the Board has asked the RRC to reschedule its review of our final classifications for the rules to an earlier date.  At its August 17, 2017 meeting, the RRC will consider whether to reschedule the RRC’s review to an earlier date.  The Board has requested that the review occur at the RRC’s meeting on September 21, 2017.
You have a right to submit public comments on our request for early review of our final rule classifications.   The only matter currently before the RRC is whether the review will occur in June 2018, as scheduled, or on an earlier date.  The substance of the categorizations will not be reviewed until September 21, 2017 (if the Board’s request is granted).

The RRC will consider objections from the public when it decides whether to grant our early review request. You have a right to submit public comments on our request for early review of our final rule classifications.  If you have an objection to the early review request, you should submit it in writing to the RRC before its August 17, 2017 meeting. You can submit your objection:



FRIDAY, JUNE 9, 2017

LUPIN PHARMACEUTICALS RECALLS LOT L600518 MIBELAS 24 FE TABLETS.  Pharmacists should be aware that Lupin Pharmaceuticals Inc. announced that it has voluntarily recalled lot L600518, Exp 05/18 of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1 mg/0.02 mg chewable and ferrous fumarate 75 mg) Tablets at the consumer level. A confirmed market complaint indicated a packaging error, where the blister was rotated 180 degrees within the wallet, reversing the weekly tablet orientation and making the lot number and expiration date no longer visible. The first four days of therapy would have had four non-hormonal placebo tablets as opposed to the active tablets.

As a result of this packaging error, oral contraceptive tablets that are taken out of sequence may place the user at  risk for contraceptive failure and unintended pregnancy. The reversing the order may not be apparent to either new users or previous users of the product, increasing the likelihood of taking the tablets out of order.
More information may be found here:



FRIDAY, MAY 26, 2017

North Carolina Board of Pharmacy Executive Director Jack "Jay" Campbell Elected Treasurer of the National Association of Boards of Pharmacy's 2017-2018 Executive Committee. Read more here:



THURSDAY, MAY 18, 2017

VIRGINIA REGULATIONS IMPOSE RESTRICTIONS ON PRESCRIBING BUPRENORPHINE WITHOUT NALOXONE (BUPRENORPHINE MONO-PRODUCT).  In March 2017, the Virginia Board of Medicine passed emergency regulations governing the prescribing of opioids and buprenorphine.  Those regulations are found here: Since those regulations went into effect, several North Carolina pharmacies have contacted Board staff to report a surge in patients with Virginia addresses presenting prescriptions for buprenorphine mono-product from North Carolina-based clinics.  Pharmacists are reminded of their obligation to use good, professional judgment when assessing whether a prescription for a controlled substance was written for a legitimate medical purpose in the ordinary course of medical practice.  A red flag for potentially illegitimate controlled substance prescribing is often a patient who travels a significant distance to obtain a controlled substance prescription and may also travel a significant distance seeking a pharmacy that will dispense the prescription.  Pharmacists are also reminded of resources on the Board website, including a “Red Flags” educational video ( and an education pocket card (  



TUESDAY, MAY 16, 2017

BOARD ISSUES UPDATED GUIDANCE ON THE SALE OF HEMP-DERIVED PRODUCTS.  The North Carolina Industrial Hemp Commission has issued rules that govern “industrial hemp products.”  As a result, the Board has updated its Guidance to North Carolina Pharmacies on the Sale of Products Derived From Hemp.  This updated guidance (found here) replaces the guidance document issued on March 30, 2017.




TRANSFER OF SCHEDULE III, IV, AND V CONTROLLED SUBSTANCES.  Board staff has become aware in recent days that some pharmacies have heard, or have been told, that federal law prohibits a pharmacy from transferring a Schedule III, IV, or V controlled substance prescription that was placed on file at the pharmacy, but never filled.  The asserted basis is 21 CFR 1306.25, which discusses transfers of these prescriptions for “refill purposes.”  Notwithstanding, the Board of Pharmacy has never taken the position that such transfers will subject a pharmacy to discipline.  Nor is Board staff aware of any DEA action taken against a pharmacy for transferring a valid Schedule III, IV, or V prescription to the pharmacy of the patient’s choice for purposes of initial fill.  If personnel at the DEA issue formal policy guidance stating an intent to enforce the CSA rule in a way that would prohibit such transfers, Board staff will advise pharmacists accordingly.




CE RULE CHANGES TO BECOME EFFECTIVE JANUARY 1, 2018.  The Board has completed a rulemaking making changes to the continuing education requirements for licensure renewal.  Board staff have received a number of good questions about the transition process.  This FAQ guidance answers them. 




Board rule .2201, CONTINUING EDUCATION -- HOURS: RECORDS: PROVIDERS: CORRESPONDENCE: RECIPROCITY has been amended and will go into effect on January 1, 2018. The current version of the rule remains in effect until December 31, 2017. Please follow this link for rule language, both current and as amended January 1, 2018.

Please note that pharmacists will receive information from the Board in the coming weeks on implementation of the new rules for 2018.



The North Carolina Board of Pharmacy's monthly meetings are live-streamed via YouTube. Follow the link below to subscribe to the Board's YouTube channel. (Meeting dates found here.)



Health Advisories (last updated July 2017) - Check here regularly for the latest alerts and recall notices.



Medicare/Medicaid (last updated May 12, 2015) - Check here regularly for the latest updates regarding Medicare/Medicaid.


Looking for a news item that is no longer here? Try our search page or send an email to Kristin Moore.


The North Carolina Board of Pharmacy's mission is to protect the public health, safety and welfare in pharmaceutical matters. The Board sets standards for academic and practical experience programs prior to licensure, issues permits to operate pharmacies and DME facilities, and annually renews licenses, permits and registrations.

For more information, please see About the NCBOP.

Copyright © 2006 North Carolina Board of Pharmacy
site design IV Design